more attention focused on urinary incontinence

You'll see more attention focused on urinary incontinence.

This is a big problem. More than 15 million people in North America suffer from bladder problems...only about 10% seek help.

The attention is partly fueled by interest in new extended-release versions of Ditropan (oxybutynin) and Detrol (tolterodine).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote